India Coronavirus Vaccine Market to grow with a CAGR of 8.81% through forecast period
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the India Coronavirus Vaccine Market in the forecast period, 2026-2030
According to TechSci Research report, “India
Coronavirus Vaccine Market - By Region, Competition,
Opportunities and Forecast, 2020-2030F”, India Coronavirus Vaccine
Market was values at USD 765.18 million in 2024 and is expected to USD 1259.90
Million by 2030, growing with a CAGR of 8.81% in the forecast period.
This may be attributed to collaborations and partnerships among major
companies, adopting a diverse approach to combine individual expertise and
reinforce their market standing. A large population increases the demand for
coronavirus vaccines. In high-density areas, virus transmission risks are
elevated, leading to a higher chance of outbreaks and rapid virus spread. This
elevated risk encourages more people to get vaccinated for protection. Reaching
herd immunity, where a substantial portion of the population becomes immune, is
vital to controlling the virus.
In densely populated regions, more individuals must be
vaccinated to achieve this, boosting overall demand. Larger populations
typically prompt broader public awareness campaigns. Mass promotion of
vaccination encourages individuals to receive their doses. In such areas, the
economic toll of the pandemic tends to be more severe. Widespread vaccination
becomes essential for resuming business operations and restoring normal
economic functions. Larger populations include more individuals in high-risk
categories, such as the elderly or those with pre-existing health conditions.
These people are more inclined to pursue vaccination, adding to the demand.
Scaling production has posed a major challenge in the India Coronavirus Vaccine Market, as seen globally. Expanding vaccine output demands infrastructure, equipment, and resources, such as manufacturing plants, cleanrooms, and specialized machinery. Building and outfitting new sites can be both lengthy and expensive. Scaling up also requires a skilled workforce, including technicians, quality control staff, and logistics teams. Recruiting and training this workforce presents its own difficulties. Securing a stable and consistent supply of raw materials—such as bioreactor parts, growth media, and vials—can be problematic. Global supply chain disruptions or material shortages can significantly hinder production. Upholding rigorous quality control standards is essential in vaccine manufacturing. Maintaining consistent quality across an expanded production scale adds another layer of complexity. Some vaccines demand specific temperature conditions during storage and transit. Thus, any increase in production must also be matched by expansion in cold chain infrastructure to preserve vaccine efficacy.
Browse over XX market data Figures
and spread through XX Pages and an in-depth
TOC on " India Coronavirus Vaccine Market”
India Coronavirus Vaccine Market is segmented based on
type, patient type, end-user, and by region.
Based on end user, in 2024, the India
Coronavirus Vaccine Market largest share was held by Hospitals segment
in the forecast period and is predicted to continue expanding over the coming
years. Many hospitals, both government-run and private, were
designated as vaccination centres. They had the necessary infrastructure,
healthcare staff, and equipment to facilitate the administration of vaccines.
Hospitals often have the required cold storage facilities to store and manage
vaccines with specific temperature requirements, such as vaccines that need to
be stored at ultra-low temperatures. Hospitals have a trained healthcare
workforce, including doctors, nurses, and support staff, who were involved in
the vaccination process. This ensured the safe and efficient administration of
vaccines. Hospitals are trusted healthcare institutions, and people may have
more confidence in receiving vaccines at hospitals, which can be important in
overcoming vaccine hesitancy. Hospitals are often widely distributed across
urban and rural areas, making vaccines more accessible to a broader population.
Hospitals were well-equipped to manage adverse events following vaccination and
provide immediate medical attention if necessary.
Based on region, North India is fastest
growing region in the India coronavirus vaccine market due to its high
population density, advanced healthcare infrastructure, and strong government
presence. States like Uttar Pradesh, Delhi, Haryana, and Punjab have large
urban populations, which facilitated faster vaccine deployment and higher
uptake. These areas also reported some of the highest COVID-19 caseloads during
the pandemic’s peak, driving greater urgency for vaccination coverage. The
presence of major public and private hospitals, medical research institutes,
and government health programs in the region contributed to efficient
distribution and administration of vaccines. Delhi, as the national capital,
served as a central hub for policymaking and coordination of the nationwide
vaccine rollout, with many public health campaigns and logistics operations
rooted there. North India benefited from better digital access, allowing for
higher CoWIN platform registration rates and smoother integration of digital
tools in the vaccination process. Awareness campaigns and media outreach were
also more effective in this region due to better communication infrastructure
and literacy levels. Logistical connectivity—through roads, railways, and
air routes—enabled timely supply of vaccines to urban and semi-urban centers.
As a result, North India consistently led in terms of vaccine doses
administered, healthcare outreach, and early adoption of new vaccine platforms
and technologies.
Some of the major companies
operating in the India Coronavirus Vaccine Market include:
·
Serum Institute of India Pvt. Ltd
·
Bharat Biotech International Ltd.
·
Zydus Cadila Ltd.
·
Pfizer India Ltd
·
Panacea Biotec Ltd
·
Indian Immunologicals Ltd
·
Mynvax Pvt. Ltd.
·
Biological E Ltd.,
·
Hetero Biopharma Ltd.
·
Dr Reddy's Laboratories Ltd.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“India’s Coronavirus Vaccine Market stands as a global
success story, driven by world-class manufacturing capabilities, innovation,
and affordability. Home to vaccine giants like Serum Institute and Bharat
Biotech, India produces a significant share of the world’s COVID-19 vaccines.
With cutting-edge platforms like mRNA, DNA, and intranasal vaccines, along with
robust cold chain logistics and digital tools like CoWIN, India ensures
efficient production and distribution. The country’s proactive public health policies,
skilled workforce, and global partnerships make it a hub for vaccine innovation
and export. For investors and stakeholders, India offers unmatched potential in
shaping the future of global immunization" said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based Global management consulting
firm.
"India Coronavirus Vaccine Market By Type (mRNA Based, Non-Replicating Viral Vector Based, Inactivated Vaccine), By Patient Type (Adult, Pediatric), By End User (Hospitals, Clinics, Research Institutes, Others), By Region, Competition, Opportunities and Forecast, 2020-2030F" has evaluated the
future growth potential of India Coronavirus Vaccine Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in India Coronavirus Vaccine Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com